BiomX Inc. Share Price & Technical Analysis
PHGE · $0.82 (+10.81%)
Healthcare / Biotechnology
$0.82
+10.81%
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of b…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-11% return in May, -3% avg return in past 3 year May month.
80% return in 2026, -50% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 200% | -23% | -10% | -76% | -11% | – | – | – | – | – | – | – | 80% |
| 25 | -2% | -13% | -9% | 10% | -18% | -9% | -12% | 39% | -3% | -9% | -53% | -56% | -134% |
| 24 | -12% | -11% | 105% | 11% | -11% | -17% | -37% | -46% | -16% | -27% | -8% | 3% | -66% |
| 23 | 106% | 6% | -28% | -9% | 20% | -5% | 10% | -5% | -16% | -21% | -16% | 8% | 49% |
| 22 | -6% | -5% | 33% | -24% | -51% | 3% | 26% | -31% | -37% | 6% | -21% | -35% | -142% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.57M
P/E ratio
—
52W high
$14.71
52W low
$0.36
Volume
1,22,88,350
Beta
1.03
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BiomX Inc. share price today?
- BiomX Inc. (PHGE) last traded around $0.82 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PHGE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PHGE. Download the app for real-time alerts.
- How can I analyze BiomX Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.